The evolution of the management of GRT

Article

During the advent of surgical approaches for retinal detachment repair, one of the most challenging cases a retinal surgeon may come across was a giant retinal tear. This article summarizes the history of GRT management and discusses current trends in surgical management.

The management of GRTs has evolved considerably over the decades. Early surgical techniques such as intraocular balloons (1970s), rotating tables and retinal incarceration with tacks, sutures and screws (1980s) have evolved into small gauge pars plana vitrectomy (PPV), wide field viewing systems and intraoperative perfluorocarbon liquid (PFCL) use. This article will briefly summarize the history of GRT management and discuss current trends in surgical management.

History of GRT management

Success rates in the management of GRTs are associated with the ability of the surgeon to manipulate the retinal flap back into its original configuration and maintain its position with intraoperative and postoperative tamponade. Earlier attempts were limited by an inability to effectively achieve and maintain the proper position of the retinal flap. A primary encircling scleral buckle could be successful in cases of minimally displaced GRTs with the placement of a low broad based scleral buckle. In the early 1980s, with the evolution of vitrectomy techniques, the surgeon could manipulate the GRT intraoperatively with rotating tables and intraocular gas tamponade.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.